Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating and preventing immune abnormalism disease

A technology for allergic diseases and autoimmunity, applied in the field of medicine, can solve problems such as incomplete elucidation of etiology and pathogenesis, exacerbation of glomerular immune inflammatory response, loss of skin pigmentation, etc., to achieve good anti-inflammatory and selective cell Effects of immunosuppression

Inactive Publication Date: 2008-02-06
罗河生
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The overexpression of NF-κB leads to the generation and further aggravation of glomerular immune inflammatory response
[0011] Vitiligo is a common skin disease with an incidence rate of 0.5%-1% of the world's population. It is clinically manifested as localized or generalized skin depigmentation. Its etiology and pathogenesis have not yet been fully elucidated.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating and preventing immune abnormalism disease
  • Medicine for treating and preventing immune abnormalism disease
  • Medicine for treating and preventing immune abnormalism disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] [Example 1] Asthma test-ovalbumin aerosol inhalation method and cell count of alveolar lavage fluid

[0043] Get 40 guinea pigs of 200-250 g, half male and half male, and inject 0.2 ml of 4% albumin saline solution intramuscularly into the outer right hind leg, and simultaneously intraperitoneally inject 0.2 ml of 4% aluminum hydroxide gel for sensitization. From the second day of sensitization, the animals were randomly divided into 4 groups: control group, sodium chromoside group, cycloastragenol 20 mg / kg group and astragaloside IV group, and cycloastragel alcohol and astragaloside IV group were administered intragastrically Administration, injection administration of sodium chromylate group, totally 14 days, after the last medicine, animal is put in airtight glass bell jar, after being quiet, start air compressor, spray into with the constant pressure of 53kPa (400mmHg) 3.5% ovalbumin normal saline for 30s, observe the latency period of wheezing convulsions in guinea...

Embodiment 2

[0051] [Example 2] Type I Allergy 1-Passive Skin Allergy Test (PCA)

[0052] The rats were randomly divided into 4 groups according to body weight: blank control group, sodium chromylate group, cycloastragenol 20 mg / kg group and astragaloside IV 20 mg / kg group, with half male and half male. The cycloastragenol and astragaloside IV groups were administered by intragastric administration, and the sodium chromylate group was administered by injection. The test used preventive administration, and the administration was continued for 14 days before the antigen challenge.

[0053] Preparation of antiserum: Inject the above-mentioned trichosanthes aluminum hydroxide suspension into four paws, inject 0.1ml into each paw, a total of 0.4ml. After 10-15 days of maturity, about 10ml of eyeball bloodletting, centrifuge at 3000 rpm for 15min, take the upper serum The antiserum was obtained.

[0054] Passive skin sensitization: the backs of the rats in each test group were depilated, and th...

Embodiment 3

[0061] [Example three] type I allergy 2-mast cell degranulation test

[0062] 40 SD rats were randomly divided into 4 groups according to body weight: blank control group, cromolyn sodium, cycloastragenol 20mg / kg group and astragaloside IV 20mg / kg group, 10 rats in each group, half male and half female, administered once / d, continuous administration for 14 days. 0.1-0.2 ml of anti-ovalbumin serum diluted 1:5 was subcutaneously injected into the head of the rat, and 48 hours later, 1 mg of ovalbumin-Evans blue solution was injected into the tail vein for challenge. The animals were killed 30 minutes after the challenge, the skin of the head was peeled off, the skull was removed, treated with 95% ethanol for 1 hour, and then put into anhydrous methanol overnight. After the mast cells were treated with 0.18% neutral red, they were rinsed with running water, one side of the skull was fixed on a small wooden board with a pin, the periosteum was carefully peeled off with tweezers,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to medical use of astragalus saponin adopting cyclo astragenol as aglycon, wherein astragaloside ó¶ and cyclo astragenol are representative compounds of astragalus saponin. Astragalus saponin can effectively cure and prevent abnormal immunity diseases such as asthma, allergic rhinitis, allergic dermatosis, systemic lupus erythematosus, rheumatoid arthritis and mesangial proliferative glomerulonephritis, etc. During being used in curing the diseases, astragalus saponin is characterized by less toxicity, definite curative effect and being suitable for long-term use, etc.; meanwhile, astragalus saponin can be made into different dosage forms with medically acceptable vehicle to cure prevent abnormal immunity diseases.

Description

field of invention [0001] The invention relates to the field of medicine, and relates to the medical application of cycloastragenol and astragaloside IV extracted from the plant Astragalus membranaceus, and cycloastragenol and astragaloside IV can effectively treat and prevent immune abnormal diseases, and the immune abnormal diseases include asthma symptoms , Allergic rhinitis, allergic skin diseases, systemic lupus erythematosus, rheumatoid arthritis, mesangial proliferative glomerulonephritis, etc. Background technique [0002] Allergic asthma, allergic rhinitis and other diseases are the most common multiple chronic respiratory diseases in the world. In recent years, diseases such as allergic asthma and allergic rhinitis have become serious public health problems due to the increasing morbidity and mortality. The research and development of new drugs, treatment methods and prevention of such diseases have received great attention from all over the world. [0003] In th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61K31/7048A61K9/08A61P37/08A61P37/00A61P13/12
Inventor 罗河生
Owner 罗河生
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com